Developer docs
API playgroundTry for free, no card

Search company profiles

PULMOTREE

Full company profile

uuid000bu4d

Namestring
PULMOTREE
Legal namestring
Pulmotree Medical GmbH
Websiteurl
pulmotree.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Pulmotree Medical GmbH is a Munich-based life-science startup specializing in respiratory drug deposition and integrated inhalation therapies. The company's core product is the Kolibri Mesh Nebulizer, a vibrating mesh nebulizer platform featuring guided inhalation with haptic feedback, an Intelligent Administration System (INAS) for breath-triggered aerosol generation, and a Key & Lock mechanism that restricts the device to approved drugs. Complementary products include the Flamingo Spirometer (CE-marked and FDA-approved mobile lung function monitor measuring FEV1, FVC, and PEF), the Connect App, and the Connect Eco-System — a networked platform that links nebulizers, inhalers, and monitoring devices with patients, physicians, and clinical study centers for adherence monitoring, inhalation quality feedback, and remote therapy optimization. Pulmotree also develops APEX, a proprietary model for predicting pulmonary drug deposition from real-time breathing profiles.\n\nPulmotree operates as a B2B technology partner to pharmaceutical and biotech companies developing inhaled biologics and nebulized therapies, providing the Kolibri as the device component of drug-device combination products under a one-stop-shop model spanning concept through production. Revenue is generated through licensing of the Kolibri platform (upfront fees, development milestones, per-unit royalties), co-development service fees with pharma partners, hardware sales of Kolibri and Flamingo devices (including supply to CROs for clinical trials), and consulting services for respiratory drug delivery. GTM is anchored in scientific credibility — the CEO is an ISAM Board Member and conference chairman — and driven by enterprise field sales, conference presence (ISAM, RDD, DDL, ERS, PDD, ATS), and scientific publications.

Short descriptiontext

Pulmotree is a Munich-based life-science startup that develops the Kolibri Mesh Nebulizer and connected respiratory therapy ecosystem for pharmaceutical partners, CROs, physicians, and patients needing precise inhaled drug delivery and adherence monitoring.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMunich, Germany
HQ citystring
Munich
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory drug delivery, mesh nebulizer platform, inhalation therapy devices, drug-device combinations, connected medical devices
Industry1 code
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
Product category
Inhalation drug delivery devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing of Kolibri Mesh Nebulizer Platform
TypeLicensing Royalties
Description

Licensing the Kolibri mesh nebulizer technology to pharmaceutical partners for drug-device combination products. The platform is customized for specific medications, patient groups, and market strategies. Revenue is generated through upfront licensing fees, development milestones, and per-unit royalties.

pulmotree.com
2Co-development Partnerships with Pharma
TypeProfessional Services
Description

Joint development of combination products with pharmaceutical companies. Partners receive full development support from concept to production under a one-stop-shop model. Revenue includes development fees, regulatory milestone payments, and commercial royalties.

pulmotree.com
3Device Sales (Kolibri, Flamingo Spirometer)
TypeHardware Sales
Description

Sale of proprietary medical devices — Kolibri mesh nebulizer and Flamingo spirometer — through pharmaceutical partnerships and potentially direct channels. Devices are also used in clinical trial settings with CROs.

pulmotree.com
4Consulting Services
TypeProfessional Services
Description

Medical and consulting services for respiratory drug delivery, spanning from product conception to production. Includes expertise in aerosol therapy, regulatory affairs, and clinical development support.

pulmotree.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Kolibri Mesh-Nebulizer
Description

Vibrating mesh nebulizer with guided inhalation technology, haptic feedback, and intelligent administration system for optimal lung deposition

pulmotree.com
+3 more records
Core offering1 text field

PULMOTREE develops and licenses a vibrating mesh nebulizer platform (Kolibri) with guided inhalation technology, haptic feedback, and a connected therapy ecosystem for targeted pulmonary drug delivery. The company works with pharmaceutical and biotech partners on drug-device combination products from concept through production, and also sells the Flamingo spirometer and Connect App as complementary devices within its Connect Eco-System. Revenue is generated via platform licensing with milestone and royalty payments, co-development fees, device sales, and consulting services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Higher deposition in target lung regions demonstrated for OCK4 (a heparin derivative) compared to spontaneous unguided breathing, as shown in a collaborative case study with Aptar Pharma using Kolibri guided breathing profile.
+3 more records
Product overview1 text field

PULMOTREE offers a platform-plus-modules product portfolio centered on the Connect Eco-System, a fully networked therapy platform for respiratory diseases. The core product is the Kolibri Mesh-Nebulizer, a vibrating mesh nebulizer with guided inhalation technology, haptic feedback, and the Intelligent Administration System (INAS) for breath-triggered aerosol delivery. Complementary modules include the Flamingo Spirometer (CE/FDA-cleared mobile lung function monitor) and the Connect App (smartphone interface for therapy control, adherence monitoring, and inhalation quality feedback). Products are designed for Plug & Play interoperability within the ecosystem, supporting both PULMOTREE's own devices and partner devices, with data transmitted to physicians and clinical study centers.

Product and service4 records
1Kolibri Mesh-Nebulizer
CategoryInhalation drug delivery devices (mesh nebulizers)
Description

Vibrating mesh nebulizer platform with guided inhalation technology, haptic feedback, and Intelligent Administration System (INAS) for breath-triggered aerosol generation; customized for pharmaceutical partners as the device component of drug-device combination products and supplied to CROs for clinical trials.

2Flamingo Spirometer
CategoryRespiratory diagnostics (spirometry)
Description

Mobile, app-based spirometer for measuring FEV1, FVC, and PEF with validated accuracy per ISO 26782, ISO 23747, and ATS/ERS 2005 standards; CE-marked and FDA-approved; used by patients at home and clinicians for lung function monitoring and integrated into the Connect Eco-System.

3Connect App
CategoryDigital health software (therapy companion app)
Description

Smartphone application providing therapy planning and reminders, digital inhalation feedback for optimal drug deposition, centralized device control, personal therapy diary, and long-term therapy and lung function monitoring; enables remote physician support and partner-system integration.

4Connect Eco-System
CategoryConnected health platform / medical device ecosystem
Description

Networked therapy platform that connects Pulmotree's nebulizers, inhalers, and monitoring devices with patients and physicians, providing automatic therapy data storage, encrypted data exchange, adherence monitoring, inhalation quality assessment, centralized therapy control, and remote patient monitoring; supports Plug & Play integration of partner devices for CROs and clinical study sites.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or Integration
Description

Aptar Pharma collaborated with Pulmotree to develop the Kolibri Mesh Nebuliser featuring guided inhalation technology with haptic feedback for biologic delivery. A collaborative case study demonstrated the Kolibri guided breathing profile achieved higher deposition in target regions for OCK4 (a heparin derivative) compared to spontaneous unguided breathing. Jonathan Mulpas from Aptar is listed as a partnering contact.

Strategic tierMinorTypeOthers
Description

KEYENCE supplied Pulmotree with a digital microscope for lab expansion, enhancing R&D capabilities. The microscope enables more precise tailoring of mesh structures, deeper understanding of aerosol generators, and more targeted drug delivery solutions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated with Pulmotree researchers on the RDD2026 poster 'Predicting Pulmonary Drug Deposition Using Real-Time Connected Inhalation Data.' DZL researchers Otmar Schmid contributed expertise in deposition modeling alongside Pulmotree's connected device data.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated with Pulmotree on pulmonary drug deposition prediction research presented at RDD2026. Otmar Schmid from Helmholtz Munich co-authored the research on integrating real-time inhalation data with in silico deposition modeling.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

CEO Ulf Krueger serves as PhD student mentor for the TANDEM program at RWTH Aachen University, supporting doctoral research in aerosol medicine and inhalation technology.

6International Society for Aerosols in Medicine (ISAM)
Strategic tierCoreTypeOthers
Description

Pulmotree CEO Ulf Krueger is a Board Member of ISAM and serves as chairman of the networking group 'New Devices, Emerging Therapies and e-Health.' The company actively participates in ISAM Congress events and the society's podcast.

pulmotree.com
7PDD Workshop Sponsors (including Miccados, Harro Höfliger, Aerogen, Amcor, GS Bio-Inhalation, MEGGLE, H&T Presspart, Resyca, Copley Scientific, IMA Group, Intertek, Insmed, PureIMS, Catalent, DFE Pharma)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Pulmotree sponsored the 11th PDD Workshop alongside multiple industry companies including Miccados, Harro Höfliger, Aerogen, Amcor, GS Bio-Inhalation, MEGGLE, H&T Presspart, Resyca, Copley Scientific, IMA Group, Intertek, Insmed, PureIMS, Catalent, and DFE Pharma, demonstrating active engagement in the respiratory drug delivery community.

pulmotree.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Partnered with Pulmotree Consulting to deliver a 4-hour German-language webinar on 'medical device and combination product labeling.' Paul Malinovski and Beate Seidel served as trainers alongside Pulmotree.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

CEO Ulf Krueger held various positions in the research and development department at PARI before founding Pulmotree. PARI is a leading company in inhalation therapy systems.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

CEO Ulf Krueger previously served as Director of Fox Nebuliser Programs at Vectura, responsible for the entire mesh nebulizer business. This prior experience informed Pulmotree's technology development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Established manufacturer of nebulizer systems for respiratory drug delivery. Pulmotree's CEO previously held R&D roles at PARI, and PARI competes in the same vibrating-mesh / breath-enhanced nebulizer category that Kolibri targets.

TypeDirect peer
Description

Specialist in vibrating-mesh aerosol drug-delivery technology used in acute and critical-care nebulization. Aerogen is a direct technological peer to Kolibri, competing for inhaled-drug combination-product partnerships with the same pharma customers.

TypeDirect peer
Description

Inhalation drug-delivery developer where Pulmotree's CEO was previously Director of Fox Nebuliser Programs. Vectura develops nebulizer and DPI platforms for pharma combination products and is a direct comparator in mesh-nebulizer business strategy.

TypeBroad incumbent
Description

Global drug-delivery device and component supplier that is Pulmotree's disclosed co-development partner for Kolibri. Aptar competes in adjacent device categories (DPIs, spray pumps, elastomeric components) and serves the same pharma combination-product market.

5OMRON Healthcare
TypeBroad incumbent
Description

Large medical-device company with a respiratory portfolio including nebulizers and connected respiratory monitoring. OMRON is a broader incumbent rather than a direct mesh-nebulizer peer but competes for similar patient and clinical customers.

TypeEmerging player
Description

Specialist in inhalation drug-device combination products with a focus on dry-powder and unit-dose systems. PureIMS is a comparable emerging combination-product developer targeting the same pharma partner pipeline.

TypeEmerging player
Description

Biopharma company that has commercialized ARIKAYCE delivered via a mesh-nebulizer pathway (PARI/eFlow). Insmed represents an example customer archetype for Pulmotree - inhaled therapies whose delivery device is mission-critical.

TypeOthers
Description

Supplier of testing equipment and reference instruments for inhaled drug-delivery development (cascade impactors, flow meters). Sits in Pulmotree's ecosystem as a tools vendor used across the same pharma development workflows.

TypeBroad incumbent
Description

Large CDMO with significant inhalation and drug-device combination-product capabilities. Catalent is a broader incumbent competing for the same pharma combination-product co-development deals, including as a co-sponsor at PDD alongside Pulmotree.

TypeOthers
Description

Sensor manufacturer whose flow and pressure sensors are commonly integrated into connected nebulizers and spirometers. Sensirion supplies enabling technology for the kind of inhalation-quality and breathing-profile data capture that Kolibri and Flamingo rely on.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PULMOTREE

Inhalation drug delivery devicespulmotree.com

Pulmotree is a Munich-based life-science startup that develops the Kolibri Mesh Nebulizer and connected respiratory therapy ecosystem for pharmaceutical partners, CROs, physicians, and patients needing precise inhaled drug delivery and adherence monitoring.

What PULMOTREE does

Pulmotree Medical GmbH is a Munich-based life-science startup specializing in respiratory drug deposition and integrated inhalation therapies. The company's core product is the Kolibri Mesh Nebulizer, a vibrating mesh nebulizer platform featuring guided inhalation with haptic feedback, an Intelligent Administration System (INAS) for breath-triggered aerosol generation, and a Key & Lock mechanism that restricts the device to approved drugs. Complementary products include the Flamingo Spirometer (CE-marked and FDA-approved mobile lung function monitor measuring FEV1, FVC, and PEF), the Connect App, and the Connect Eco-System — a networked platform that links nebulizers, inhalers, and monitoring devices with patients, physicians, and clinical study centers for adherence monitoring, inhalation quality feedback, and remote therapy optimization. Pulmotree also develops APEX, a proprietary model for predicting pulmonary drug deposition from real-time breathing profiles.\n\nPulmotree operates as a B2B technology partner to pharmaceutical and biotech companies developing inhaled biologics and nebulized therapies, providing the Kolibri as the device component of drug-device combination products under a one-stop-shop model spanning concept through production. Revenue is generated through licensing of the Kolibri platform (upfront fees, development milestones, per-unit royalties), co-development service fees with pharma partners, hardware sales of Kolibri and Flamingo devices (including supply to CROs for clinical trials), and consulting services for respiratory drug delivery. GTM is anchored in scientific credibility — the CEO is an ISAM Board Member and conference chairman — and driven by enterprise field sales, conference presence (ISAM, RDD, DDL, ERS, PDD, ATS), and scientific publications.

PULMOTREE firmographics

Firmographics
Name
PULMOTREE
Legal name
Pulmotree Medical GmbH
Website
https://pulmotree.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Pulmotree is a Munich-based life-science startup that develops the Kolibri Mesh Nebulizer and connected respiratory therapy ecosystem for pharmaceutical partners, CROs, physicians, and patients needing precise inhaled drug delivery and adherence monitoring.
Ownership category
akta.pro rank

PULMOTREE industry classification

Industry
Product category
Inhalation drug delivery devices
akta.pro industry
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Respiratory drug delivery
  • Mesh nebulizer platform
  • Inhalation therapy devices
  • Drug-device combinations
  • Connected medical devices

Where PULMOTREE is headquartered

Location

Headquarters

HQ city
Munich
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

PULMOTREE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Licensing of Kolibri Mesh Nebulizer Platform: Licensing the Kolibri mesh nebulizer technology to pharmaceutical partners for drug-device combination products. The platform is customized for specific medications, patient groups, and market strategies. Revenue is generated through upfront licensing fees, development milestones, and per-unit royalties.
  2. Co-development Partnerships with Pharma: Joint development of combination products with pharmaceutical companies. Partners receive full development support from concept to production under a one-stop-shop model. Revenue includes development fees, regulatory milestone payments, and commercial royalties.
  3. Device Sales (Kolibri, Flamingo Spirometer): Sale of proprietary medical devices — Kolibri mesh nebulizer and Flamingo spirometer — through pharmaceutical partnerships and potentially direct channels. Devices are also used in clinical trial settings with CROs.
  4. Consulting Services: Medical and consulting services for respiratory drug delivery, spanning from product conception to production. Includes expertise in aerosol therapy, regulatory affairs, and clinical development support.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels11 records

PULMOTREE product offering

Product offering

Core offering

PULMOTREE develops and licenses a vibrating mesh nebulizer platform (Kolibri) with guided inhalation technology, haptic feedback, and a connected therapy ecosystem for targeted pulmonary drug delivery. The company works with pharmaceutical and biotech partners on drug-device combination products from concept through production, and also sells the Flamingo spirometer and Connect App as complementary devices within its Connect Eco-System. Revenue is generated via platform licensing with milestone and royalty payments, co-development fees, device sales, and consulting services.

Product overview

PULMOTREE offers a platform-plus-modules product portfolio centered on the Connect Eco-System, a fully networked therapy platform for respiratory diseases. The core product is the Kolibri Mesh-Nebulizer, a vibrating mesh nebulizer with guided inhalation technology, haptic feedback, and the Intelligent Administration System (INAS) for breath-triggered aerosol delivery. Complementary modules include the Flamingo Spirometer (CE/FDA-cleared mobile lung function monitor) and the Connect App (smartphone interface for therapy control, adherence monitoring, and inhalation quality feedback). Products are designed for Plug & Play interoperability within the ecosystem, supporting both PULMOTREE's own devices and partner devices, with data transmitted to physicians and clinical study centers.

Differentiator

Problem solved

Functional benefit

Brands

  • Kolibri Mesh-Nebulizer: Vibrating mesh nebulizer with guided inhalation technology, haptic feedback, and intelligent administration system for optimal lung deposition
  • Connect Eco-System
  • Flamingo Spirometer
  • Connect App

Products and services

  • Kolibri Mesh-Nebulizer Vibrating mesh nebulizer platform with guided inhalation technology, haptic feedback, and Intelligent Administration System (INAS) for breath-triggered aerosol generation; customized for pharmaceutical partners as the device component of drug-device combination products and supplied to CROs for clinical trials.
  • Flamingo Spirometer Mobile, app-based spirometer for measuring FEV1, FVC, and PEF with validated accuracy per ISO 26782, ISO 23747, and ATS/ERS 2005 standards; CE-marked and FDA-approved; used by patients at home and clinicians for lung function monitoring and integrated into the Connect Eco-System.
  • Connect App Smartphone application providing therapy planning and reminders, digital inhalation feedback for optimal drug deposition, centralized device control, personal therapy diary, and long-term therapy and lung function monitoring; enables remote physician support and partner-system integration.
  • Connect Eco-System Networked therapy platform that connects Pulmotree's nebulizers, inhalers, and monitoring devices with patients and physicians, providing automatic therapy data storage, encrypted data exchange, adherence monitoring, inhalation quality assessment, centralized therapy control, and remote patient monitoring; supports Plug & Play integration of partner devices for CROs and clinical study sites.

Quantifiable outcome

  • Higher deposition in target lung regions demonstrated for OCK4 (a heparin derivative) compared to spontaneous unguided breathing, as shown in a collaborative case study with Aptar Pharma using Kolibri guided breathing profile.
  • +3 more outcomes

Companies that use PULMOTREE

Customer profile

Segments4 records

Ideal customer profiles3 records

PULMOTREE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

PULMOTREE partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Aptar PharmacoreTechnology or IntegrationAptar Pharma collaborated with Pulmotree to develop the Kolibri Mesh Nebuliser featuring guided inhalation technology with haptic feedback for biologic delivery. A collaborative case study demonstrated the Kolibri guided breathing profile achieved higher deposition in target regions for OCK4 (a heparin derivative) compared to spontaneous unguided breathing. Jonathan Mulpas from Aptar is listed as a partnering contact.
  • KEYENCEminorOthersKEYENCE supplied Pulmotree with a digital microscope for lab expansion, enhancing R&D capabilities. The microscope enables more precise tailoring of mesh structures, deeper understanding of aerosol generators, and more targeted drug delivery solutions.
  • German Center for Lung Research (DZL)coreStrategic or Co-development PartnerCollaborated with Pulmotree researchers on the RDD2026 poster 'Predicting Pulmonary Drug Deposition Using Real-Time Connected Inhalation Data.' DZL researchers Otmar Schmid contributed expertise in deposition modeling alongside Pulmotree's connected device data.
  • Helmholtz MunichcoreStrategic or Co-development PartnerCollaborated with Pulmotree on pulmonary drug deposition prediction research presented at RDD2026. Otmar Schmid from Helmholtz Munich co-authored the research on integrating real-time inhalation data with in silico deposition modeling.
  • RWTH Aachen University (TANDEM Program)minorStrategic or Co-development PartnerCEO Ulf Krueger serves as PhD student mentor for the TANDEM program at RWTH Aachen University, supporting doctoral research in aerosol medicine and inhalation technology.
  • International Society for Aerosols in Medicine (ISAM)coreOthersPulmotree CEO Ulf Krueger is a Board Member of ISAM and serves as chairman of the networking group 'New Devices, Emerging Therapies and e-Health.' The company actively participates in ISAM Congress events and the society's podcast.
  • PDD Workshop Sponsors (including Miccados, Harro Höfliger, Aerogen, Amcor, GS Bio-Inhalation, MEGGLE, H&T Presspart, Resyca, Copley Scientific, IMA Group, Intertek, Insmed, PureIMS, Catalent, DFE Pharma)minorGTM or Marketing PartnerPulmotree sponsored the 11th PDD Workshop alongside multiple industry companies including Miccados, Harro Höfliger, Aerogen, Amcor, GS Bio-Inhalation, MEGGLE, H&T Presspart, Resyca, Copley Scientific, IMA Group, Intertek, Insmed, PureIMS, Catalent, and DFE Pharma, demonstrating active engagement in the respiratory drug delivery community.
  • PAConsult GmbHminorImplementation/ SI/ Consulting PartnerPartnered with Pulmotree Consulting to deliver a 4-hour German-language webinar on 'medical device and combination product labeling.' Paul Malinovski and Beate Seidel served as trainers alongside Pulmotree.
  • PARIminorStrategic or Co-development PartnerCEO Ulf Krueger held various positions in the research and development department at PARI before founding Pulmotree. PARI is a leading company in inhalation therapy systems.
  • VecturaminorStrategic or Co-development PartnerCEO Ulf Krueger previously served as Director of Fox Nebuliser Programs at Vectura, responsible for the entire mesh nebulizer business. This prior experience informed Pulmotree's technology development.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

PULMOTREE competitors and assessment

Company assessment

Direct peers

  • PARI: Established manufacturer of nebulizer systems for respiratory drug delivery. Pulmotree's CEO previously held R&D roles at PARI, and PARI competes in the same vibrating-mesh / breath-enhanced nebulizer category that Kolibri targets.
  • Aerogen: Specialist in vibrating-mesh aerosol drug-delivery technology used in acute and critical-care nebulization. Aerogen is a direct technological peer to Kolibri, competing for inhaled-drug combination-product partnerships with the same pharma customers.
  • Vectura (Philip Morris): Inhalation drug-delivery developer where Pulmotree's CEO was previously Director of Fox Nebuliser Programs. Vectura develops nebulizer and DPI platforms for pharma combination products and is a direct comparator in mesh-nebulizer business strategy.

Broad incumbents

  • Aptar Pharma: Global drug-delivery device and component supplier that is Pulmotree's disclosed co-development partner for Kolibri. Aptar competes in adjacent device categories (DPIs, spray pumps, elastomeric components) and serves the same pharma combination-product market.
  • OMRON Healthcare: Large medical-device company with a respiratory portfolio including nebulizers and connected respiratory monitoring. OMRON is a broader incumbent rather than a direct mesh-nebulizer peer but competes for similar patient and clinical customers.
  • Catalent: Large CDMO with significant inhalation and drug-device combination-product capabilities. Catalent is a broader incumbent competing for the same pharma combination-product co-development deals, including as a co-sponsor at PDD alongside Pulmotree.

Emerging players

  • PureIMS: Specialist in inhalation drug-device combination products with a focus on dry-powder and unit-dose systems. PureIMS is a comparable emerging combination-product developer targeting the same pharma partner pipeline.
  • Insmed (inhaled antibiotic franchise): Biopharma company that has commercialized ARIKAYCE delivered via a mesh-nebulizer pathway (PARI/eFlow). Insmed represents an example customer archetype for Pulmotree - inhaled therapies whose delivery device is mission-critical.

Others

  • Copley Scientific: Supplier of testing equipment and reference instruments for inhaled drug-delivery development (cascade impactors, flow meters). Sits in Pulmotree's ecosystem as a tools vendor used across the same pharma development workflows.
  • Sensirion: Sensor manufacturer whose flow and pressure sensors are commonly integrated into connected nebulizers and spirometers. Sensirion supplies enabling technology for the kind of inhalation-quality and breathing-profile data capture that Kolibri and Flamingo rely on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

PULMOTREE social profiles

Digital presence

PULMOTREE compliance and trust

Trust signal

Compliance5 records

PULMOTREE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PULMOTREE leadership team

Management profile

Number of profiles

Profiles5 records

PULMOTREE funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PULMOTREE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PULMOTREE

What does PULMOTREE do?

PULMOTREE develops and licenses a vibrating mesh nebulizer platform (Kolibri) with guided inhalation technology, haptic feedback, and a connected therapy ecosystem for targeted pulmonary drug delivery. The company works with pharmaceutical and biotech partners on drug-device combination products from concept through production, and also sells the Flamingo spirometer and Connect App as complementary devices within its Connect Eco-System. Revenue is generated via platform licensing with milestone and royalty payments, co-development fees, device sales, and consulting services.

Is PULMOTREE a public or private company?

PULMOTREE is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was PULMOTREE founded?

PULMOTREE was founded in 2018. It employs 11 to 50 people.

Where is PULMOTREE based?

PULMOTREE is headquartered in Munich, Germany, in the Europe region.

How does PULMOTREE make money?

Four revenue lines are on record. Licensing of Kolibri Mesh Nebulizer Platform is the primary driver. The others are co-development Partnerships with Pharma, device Sales (Kolibri, Flamingo Spirometer) and consulting Services.

Who are PULMOTREE's main competitors?

Direct peers on record are PARI, Aerogen and Vectura (Philip Morris). Broad incumbents are Aptar Pharma, OMRON Healthcare and Catalent. Emerging players are PureIMS and Insmed (inhaled antibiotic franchise). Others are Copley Scientific and Sensirion.

Does PULMOTREE have an API?

No public API is recorded for PULMOTREE.

What industry is PULMOTREE in?

PULMOTREE's product category is Inhalation drug delivery devices. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Aptar Pharma Acquires PULMOTREE To Expand Pulmonary Drug Delivery PlatformAptar Pharma acquired Munich-based PULMOTREE, adding its Kolibri non-propellant liquid inhaler platform to its respiratory drug delivery portfolio. The breath-triggered device supports complex inhaled therapies, including biologics, and Aptar plans to integrate it with its existing capabilities. The acquisition expands Aptar's position in respiratory drug delivery.Seeking AlphaAptar Pharma acquires Pulmotree (ATR:NYSE)Aptar Pharma announced the strategic acquisition of Pulmotree, a Munich-based life science company specializing in pulmonary drug delivery systems. The deal is expected to accelerate the development, industrialization, and commercialization of Pulmotree's Kolibri Non-Propellant Liquid Inhaler platform.citybizAptar Pharma Acquires Pulmotree to Expand Pulmonary Drug Delivery TechnologyAptar Pharma acquired Munich-based Pulmotree to expand its pulmonary drug delivery portfolio. The deal accelerates development of Kolibri, a non-propellant liquid inhaler with breath-triggered vibrating mesh aerosolization. Financial terms were not disclosed.Investing.comAptar Pharma acquires Pulmotree to expand inhaler portfolioAptar Pharma acquired Munich-based Pulmotree, adding its Kolibri non-propellant liquid inhaler platform to its respiratory drug delivery portfolio. The breath-triggered vibrating mesh aerosolization engine targets lung delivery and includes connectivity for treatment monitoring. Financial terms were not disclosed.FinancialContent Business PageAptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug DeliveryAptar Pharma acquired Pulmotree, a Munich-based pulmonary drug delivery company, to accelerate development and commercialization of its Kolibri Non-Propellant Liquid Inhaler platform. The acquisition aims to expand Aptar's respiratory drug delivery portfolio and support delivery of complex molecules, including biologics.Stock TitanAptar Pharma acquires Pulmotree, adding Kolibri inhalerAptar Pharma acquired Pulmotree, a Munich-based pulmonary drug delivery company, to accelerate development and commercialization of its Kolibri non-propellant liquid inhaler platform. The acquisition expands Aptar's respiratory drug delivery portfolio and aims to support complex molecules, including biologics, with a goal of providing a pathway from development to market launch.AptarInnovations in Pulmonary Care: DPI and NPLI Lead the WayThe article discusses advances in inhaled drug delivery technologies, specifically focusing on Dry Powder Inhalers (DPIs) and Non-Propellant Liquid Inhalers (NPLIs), which are reshaping the respiratory care market. Key details include the introduction of innovative products such as Aptar Pharma's Quattri DPI and the Kolibri Digital NPLI in collaboration with PULMOTREE, which both enhance drug delivery capabilities. The ongoing research and development in inhalation technologies suggest a significant transformation in respiratory treatments and patient care.AptarKolibri™: Precision Inhalation for Biologics with Guided BreathingPULMOTREE, in collaboration with Aptar Pharma, developed the Kolibri™ Mesh Nebuliser featuring guided inhalation technology with haptic feedback to optimize aerosol performance and ensure precise drug deposition in targeted lung regions for biologic delivery. The device uses realistic breathing profiles in in vitro and in silico testing to improve predictive accuracy of aerosol drug delivery systems and reduce late-stage development failures. A collaborative case study demonstrated that the Kolibri guided breathing profile achieved higher deposition in target regions for OCK4, a heparin derivative, compared to spontaneous unguided breathing.YahooAptar Pharma Enters into Exclusive Agreement with Pulmotree to Develop and Promote Kolibri™ Non-Propellant Liquid Inhaler PlatformAptar Pharma entered an exclusive agreement with Pulmotree to develop and promote the Kolibri non-propellant liquid inhaler platform. The collaboration expands Aptar's respiratory portfolio, combining Pulmotree's breath-triggered aerosolization technology with Aptar's formulation and patient onboarding services.